<DOC>
	<DOCNO>NCT00328549</DOCNO>
	<brief_summary>The purpose study describe time course extent hemoglobin ( Hb ) change erythropoietic response PEG-IFN/RBV-induced anemia In HCV-infected subject .</brief_summary>
	<brief_title>A Study Evaluate Erythropoietic Response Hepatitis C Virus ( HCV ) Patients Receiving Combination Ribavirin ( RBV ) /Interferon ( IFN ) Therapy RBV/PEG IFN ( NATURAL HISTORY-HCV )</brief_title>
	<detailed_description>Patients receive combination therapy chronic hepatitis C virus ( HCV ) infection ( standard pegylated interferon alfa [ PEG-IFN ] combination ribavirin [ RBV ] ) frequently develop moderate severe anemia . In large , prospective , clinical trial PEG-IFN alfa-2b PEG-IFN alfa-2a , report mean decrease hemoglobin ( Hb ) 2.5 g/dL 3.7 g/dL , respectively . Furthermore , retrospective study , 54 % standard interferon/RBV-treated patient hemoglobin ( Hb ) decrease least 3 g/dL . It important understand cause , natural history , risk factor associate HCV therapy-induced anemia , decrease Hb result RBV dose reduction discontinuation , may adversely affect likelihood virologic response . Erythropoietin endogenous hormone act bone marrow increase number erythroid progenitor cell . Normally , decrease Hb level accompany increase serum erythropoietin ( sEPO ) level , ultimately normalize Hb level . The relationship Hb sEPO less apparent patient chronic disease cancer human immunodeficiency virus ( HIV ) infection . It know whether HCV-infected patient receive combination PEG-IFN/RBV therapy similarly diminish erythropoietic response anemia . One hundred HCV-infected patient receive combination RBV/IFN RBV/PEG-IFN therapy enrol multicenter study . No study medication administer study . Weekly blood sample collect specified time initial 8 week RBV/IFN RBV/PEG-IFN therapy . Assessment laboratory test , vital sign , incidence severity adverse experience obtain . The objective study document pattern hemoglobin change erythropoietic response ( baseline final assessment , Week 8 ) HCV-infected patient receive combination therapy RBV/IFN RBV/PEG-IFN . N/A</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Signed Informed Consent HCV infect patient confirm PCR branch DNA ( bDNA ) Scheduled commence combination RBV/IFN RBV/PEGIFN therapy Day 1 Normal serum creatinine Life expectancy &gt; 6 month HIVinfected patient History primary hematologic disease Anemia attributable factor iron folate deficiency , pretreatment hemolysis gastrointestinal bleeding Has suspect confirm significant hepatic disease etiology HCV ( e.g . alcohol , HBV , autoimmune disease etc ) Current , active substance abuser Pregnant breast feed Women childbearing potential take adequate birth control measure Exposure Epoetin alfa within three ( 3 ) month prior study enrollment study Transfusion within three ( 3 ) month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Natural History ,</keyword>
	<keyword>Hepatitis C Infection</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Pegylated Interferon</keyword>
	<keyword>Interferon</keyword>
</DOC>